Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

GT Biopharma (GTBP) EPS (Basic) (2016 - 2021)

GT Biopharma (GTBP) has disclosed EPS (Basic) for 12 consecutive years, with $0.09 as the latest value for Q4 2021.

  • On a quarterly basis, EPS (Basic) rose 101.44% to $0.09 in Q4 2021 year-over-year; TTM through Dec 2021 was -$2.06, a 81.99% increase, with the full-year FY2025 number at -$6.68, up 3.75% from a year prior.
  • EPS (Basic) was $0.09 for Q4 2021 at GT Biopharma, up from -$0.17 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $479053.0 in Q2 2017 to a low of -$26.36 in Q1 2017.
  • A 5-year average of $25211.3 and a median of -$0.2 in 2018 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): plummeted 8140.0% in 2020, then skyrocketed 101.44% in 2021.
  • GT Biopharma's EPS (Basic) stood at $15.94 in 2017, then crashed by 129.49% to -$4.7 in 2018, then soared by 114.46% to $0.68 in 2019, then crashed by 1022.06% to -$6.27 in 2020, then surged by 101.44% to $0.09 in 2021.
  • Per Business Quant, the three most recent readings for GTBP's EPS (Basic) are $0.09 (Q4 2021), -$0.17 (Q3 2021), and -$0.15 (Q2 2021).